- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07319247
Terapia Láser y Entrenamiento de los Músculos del Suelo Pélvico para la Incontinencia Urinaria de Esfuerzo
El Efecto de la Terapia Láser de Alta Frecuencia y el Entrenamiento de los Músculos del Suelo Pélvico en Mujeres con Incontinencia Urinaria de Esfuerzo: Un Ensayo Controlado Aleatorizado con Placebo
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Konya
-
Meram, Konya, Turquía (Türkiye), (507) 534-6142
- Physical Therapy Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Criterios de inclusión:
- Mujeres de 18 a 65 años,
- Mujeres que sean voluntarias y comprometidas con el trabajo,
- Mujeres diagnosticadas con incontinencia urinaria de esfuerzo,
Criterios de exclusión:
- Embarazo,
- Cirugía previa en la zona de tratamiento en los últimos 12 meses,
- Infección genital activa,
- Presencia de malignidad,
- Uso de esteroides sistémicos en los últimos 3 meses,
- Uso de lubricante vaginal en los últimos 7 días,
- Infección urinaria recurrente o herpes genital,
- Puntuación POP-Q de 3 o superior
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Plasebo Laser
This group will only receive placebo laser treatment.
The ND: YAG laser system was configured identically, except for the addition of a metal shielding plate to the hand tool to block energy, which had no therapeutic effect, during treatment.
The laser device will be aimed at 6 points in the perineal area .
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
|
This group will only receive placebo laser treatment.
The ND: YAG laser system was configured identically, except for the addition of a metal shielding plate to the hand tool to block energy, which had no therapeutic effect, during treatment.
The laser device will be aimed at 6 points in the perineal area .
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
|
|
Comparador activo: PFME
In this training, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
According to this program, pelvic floor exercises are performed in weeks 1-2, 2 sets in weeks 3-4, 4 sets in weeks 5-6, 8 sets in weeks 7-8, and 10 sets in weeks 8-12.
Assessments will be conducted twice, baseline and post treatment (at 12 week).
|
In this training, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
According to this program, pelvic floor exercises are performed in weeks 1-2, 2 sets in weeks 3-4, 4 sets in weeks 5-6, 8 sets in weeks 7-8, and 10 sets in weeks 8-12.
Assessments will be conducted twice, baseline and post treatment (at 12 week).
|
|
Experimental: PFME and Laser Therapy
PFMT, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
Laser was also applied to this group.
Laser application is applied to 6 points in the perineal area.
Continue and biostimulatory mode, intensity 6W, energy density 120J/cm2.
Application time is 2 minutes for each point, and a total of 6 sessions are applied 3 time.
|
PFMT, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation. During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles. The image of "turning the faucet off and on" is used to help patients better understand this exercise. During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them. One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions. According to this program, pelvic floor exercises are performed in weeks 1-2, in weeks 3-4, in weeks 5-6, in weeks 8-12, and in weeks 12. Laser application is applied to 6 points in the perineal area. Continue and biostimulatory mode, intensity 6W, energy density 120J/cm2. Application time is 2 minutes for each point, and a total of 6 sessions are applied 3 time |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Urinary incontinence severity
Periodo de tiempo: baseline, post treatment (at 12 week)
|
The Incontinence Severity Index (ISI): This is a two-question questionnaire that helps calculate the severity of urinary incontinence in patients.
It categorizes incontinence severity into three groups: mild, moderate, and severe.
It is a useful method for monitoring and assessing incontinence severity.
|
baseline, post treatment (at 12 week)
|
|
The impact of urinary incontinence on quality of life
Periodo de tiempo: baseline, post treatment (at 12 week)
|
The Incontinence Quality of Life Scale (I-QOL) will be used to determine the impact of urinary incontinence on quality of life in women.
It consists of questions under three headings: behavioral, psychological, and social impact.
The questions will be asked of the participants and recorded.
|
baseline, post treatment (at 12 week)
|
|
pelvic floor dysfuntion severity
Periodo de tiempo: baseline, post treatment (at 12 week)
|
The Global Pelvic Floor Impact Questionnaire (GPTRA): This questionnaire consists of nine questions addressing pelvic floor dysfunction.
A higher total score indicates a greater degree of symptoms.
Participants were asked questions and recorded.
|
baseline, post treatment (at 12 week)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sexually Dysfunction
Periodo de tiempo: baseline, post treatment (at 12 week)
|
The Female Sexual Function Index (FSFI): It consists of nineteen separate questions. It has six subscales: desire, arousal, lubrication, orgasm, general satisfaction, and pain. Questions 3-14 and 15-19 are scored on a 6-point Likert-type scale (0-5), while the remaining questions are scored on a 5-point Likert-type scale (1-5). The scale, which can be applied to those who have had sexual intercourse within the last month, is scored negatively, with higher scores interpreted as indicating no or low sexual dysfunction. The highest possible score is 36.0, and the lowest is 2.0. The cut-off score is 26.55. Scores of 26.55 and below are considered to indicate sexual dysfunction. |
baseline, post treatment (at 12 week)
|
|
pelvic floor muscle function
Periodo de tiempo: baseline, post treatment (at 12 week)
|
Pelvic floor muscle function will be assessed with EMG biofeedback.
|
baseline, post treatment (at 12 week)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Trastornos de la micción
- Síntomas del tracto urinario inferior
- Manifestaciones Urológicas
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Incontinencia urinaria
- Incontinencia Urinaria, Estrés
- Terapéutica
- Procedimientos quirúrgicos, operativo
- Técnicas de ablación
- Terapia con láser
- metil éster de pentalenolactona F
Otros números de identificación del estudio
- hlaser
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .